多西他赛联合表柔比星新辅助化疗治疗局部进展期乳腺癌的近期疗效及对血清肿瘤标志物的影响  

Short-term efficacy of docetaxel combined with epirubicin neoadjuvant chemotherapy in the treatment of locally advanced breast cancer and its effect on serum tumor markers

作　　者：郑添之 庞至远 张强[1] ZHENG Tianzhi;PANG Zhiyuan;ZHANG Qiang(Department of Breast Surgery,Cancer Hospital of Liaoning,Shenyang 110042,Liaoning,China)

机构地区：[1]辽宁省肿瘤医院乳腺外科,沈阳110042

出　　处：《癌症进展》2018年第15期1878-1881,共4页Oncology Progress

摘　　要：目的探讨多西他赛联合表柔比星新辅助化疗治疗局部进展期乳腺癌的近期疗效及对血清肿瘤标志物的影响。方法回顾性分析96例局部进展期乳腺癌患者的病历资料。根据新辅助化疗方式的不同将患者分为观察组和对照组,每组48例。观察组患者接受多西他赛联合表柔比星新辅助化疗,对照组患者接受紫杉醇联合表柔比星新辅助化疗。比较两组患者的近期疗效及治疗前后血清肿瘤标志物水平。结果观察组患者的缓解率、疾病控制率均高于对照组,但差异均无统计学意义(P﹥0.05)。两组患者骨髓抑制、胃肠道反应、脱发、肾功能不全、肝功能不全的发生率比较,差异均无统计学意义(P﹥0.05)。治疗后,观察组患者的血清糖类抗原153(CA153)水平明显低于对照组(P﹤0.01);治疗后,观察组患者的血清癌胚抗原(CEA)、糖类抗原125(CA125)水平均低于对照组,但差异均无统计学意义(P﹥0.05)。结论多西他赛联合表柔比星新辅助化疗治疗局部进展期乳腺癌能明显降低血清肿瘤标志物水平,值得临床进一步推广研究。Objective To observe the effect of docetaxel combined with epirubicin neoadjuvant chemotherapy on the short-term efficacy and serum tumor markers of locally advanced breast cancer.Method Clinical data of 96 patients with locally advanced breast cancer were analyzed retrospectively.According to the different neoadjuvant chemotherapy,patients were divided into observation group(docetaxel combined with epirubicin neoadjuvant chemotherapy)and control group(paclitaxe combined with epirubicin neoadjuvant chemotherapy),48 cases in each group.The short-term efficacy and the serum levels of tumor markers before and after treatment of patients in two groups were compared.Result The response rate and disease control rate in observation group were both higher than those in control group,but there was no significant difference between the two groups(P>0.05).There was no significant difference in the incidences of myelosuppression,gastrointestinal reaction,alopecia,renal dysfunction and liver dysfunction of patients between the two groups(P>0.05).After treatment,the serum level of carbohydrate antigen 153(CA153)of patients in the observation group was significantly lower than that of patients in the control group(P<0.01);the serum levels of carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)of patinets in the observation group were lower than those of patients in the control group,but the differences were not statistically significant(P>0.05).Conclusion Docetaxel combined with epirubicin neoadjuvant chemotherapy for locally advanced breast cancer can significantly reduce the serum level of tumor markers,which is worthy of further clinical research.

关 键 词：乳腺癌 新辅助化疗 多西他赛 表柔比星 肿瘤标志物 

分 类 号：R737.9[医药卫生—肿瘤]